Emerging evidence suggests that disruptions in the insulin/IGF-1/growth hormone axis, characteristic of diabetes, contribute to excessive Aβ production and neurodegenerative processes, potentially driving AD pathology. The gene discussed is IGF1; the disease is Alzheimer disease.